| Send2Press.com • Today is Tuesday, February 09, 2010 | A Member of the Neotrope News Network |  |
 Search Send2Press.com: |
|
|
|
PRESS RELEASE : U.S. and World News :
Medical :
Drugs and Pharmaceuticals
News
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved
Wed, 14 Oct 2009, 05:59:50 EST Edited by Debra Tone    
Epeius Biotechnologies Reports Dose-Dependent Efficacy and Survival Benefits.SAN MARINO, Calif., Oct. 14 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G® as stand-alone therapy in chemotherapy-resistant pancreatic cancer. Following Phase I studies at the Mayo Clinic, which affirmed the general safety of Rexin-G, advanced U.S. Phase I/II studies were undertaken, which included a Phase II efficacy component and examined progressive dose escalations of Rexin-G, while monitoring objective tumor responses in a comprehensive manner. Employing these higher doses of Rexin-G led to improved tumor responses, as assessed by all available measures (RECIST, Intl. PET and CHOI criteria) and nearly tripled the expected survival time, all in a dose-dependent manner. Moreover, this U.S. study serves to establish a critical pharmacological threshold of bioactivity, for this otherwise intractable disease, by demonstrating an increase in overall survival time (measured as percent surviving 12 months) from virtually nil using low doses to more than 28 percent of the patients using high doses surviving beyond one year. By meeting all primary and secondary study endpoints of safety and efficacy, Epeius Biotechnologies' Rexin-G has succeeded in an area of clinical oncology where many promising biologics have simply failed to deliver. By achieving both progression-free survival and overall survival benefits in pancreas cancer, while avoiding untoward systemic or dose-limiting toxicities, Rexin-G has raised the bar for the entire biopharmaceutical industry, as it inaugurates the emerging field of precision-targeted genetic medicine. The outstanding results of this advanced U.S. clinical trial confirm the results of previous preclinical and clinical studies conducted in the Philippines (where Rexin-G is approved for all solid tumors), and demonstrate beyond contestation that Rexin-G, at these effective dose levels, exhibits profound anti-tumor activity when administered as a single therapeutic agent in otherwise intractable Stage IV pancreatic cancer. The success of these landmark studies is a tribute, not only to the clinical investigators who "held the course" and the "cause" of a better medicine as a high standard, but to the U.S. FDA who, by allowing across-the-board dose escalations in ongoing trials for sarcoma, breast, and pancreas cancer (once general safety was established), served to expedite the achievement of these effective doses, and thus these heartening results. The full article, authored by Dr. Sant P. Chawla et al., is now available online (Molecular Therapy, Oct 13, 2009; see Advance Online Publications: www.nature.com/mt/). About Epeius Biotechnologies: Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products, Rexin-G and Reximmune-C, and its high-performance gene delivery systems. More Information: To learn more about these agents and/or ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com, or visit: www.epeiusbiotech.com.
NEWS SOURCE: Epeius Biotechnologies Corporation
Send2Press® is the originating wire service for this story. Terms of Use
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE (Epeius Biotechnologies Corporation), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Latest News from Send2Press Newswire:
Additional News on Similar Topics:
|
Additional Related News from
Epeius Biotechnologies Corporation
Reader Resources
Main Send2Press® News Channels
Subscribe to Weekly News Alert
from Send2Press Newswire
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
MEDIA READS (by media and public, as of today): 2290 times (15 today, 47 this week,
154 this month, 702 this year)
Site Design and Content is Copr. © 1983 - 2010 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Headline Feeds | Podcast | PR News Channels | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Google
Reddit
Diigo
Delicious
Yahoo!
Digg
Blinklist
Blogmarks
Mixx
Facebook
Newsvine
